- $6.05bn
- $5.19bn
- $147.17m
Grail's cancer blood test nears landmark FDA approval, but insurance coverage looms
U.S. RESEARCH ROUNDUP-Chevron, Mobility Global, Tesla
Street View: Grail cancer test's progress boosts prospects for multi-cancer detection market
NASDAQ RESUMED AT 07:05 AM
Street View: Grail cancer test's progress boosts prospects for multi-cancer detection market
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
Press Digest: Wall Street Journal - September 24
US FDA advisers endorse Grail cancer test's benefits in key vote (updated)
FDA advisers back safety of Grail's cancer test, narrowly endorses efficacy
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM
Grail rallies as FDA staff flags no major concerns for multi-cancer test
Grail jumps as FDA raises no major concerns on cancer test
Brief: Grail Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: GRAIL Says FDA Advisory Committee To Review GRAIL Galleri PMA Application On September 23
US FDA to hold advisory meeting to review Grail's multi-cancer test (updated)
US FDA to hold advisory meeting to review Grail's multi-cancer test
Grail Inc reports results for the quarter ended June 30 - Earnings Summary
Grail Q2 revenue rises 26%, net loss narrows 3%
Grail Inc expected to post a loss of $2.65 a share - Earnings Preview